Kopran reported a 10% year-on-year decline in consolidated net profit to ₹670.09 lakh for the first quarter ended June 30, 2026 (Q1FY26), despite top-line revenue growing to ₹1,539.94 lakh. The pharmaceutical manufacturer’s Board of Directors approved the unaudited standalone and consolidated financial results on August 7, 2026, revealing that rising input costs and operational expenses eroded operating leverage. While absolute earnings before interest, tax, depreciation, and amortisation (EBITDA) improved to ₹178.39 lakh, the EBITDA margin contracted by 67 basis points to 11.55% from 12.22% in the corresponding quarter of FY25. The results were reviewed by statutory auditor Khandelwal Jain & Co., which issued an unmodified opinion.

Revenue and Operating Performance

Kopran’s consolidated revenue from operations rose 13.8% year-on-year to ₹1,539.94 lakh in Q1FY26, compared to ₹1,352.16 lakh in Q1FY25. This growth was driven by increased volume and mix improvements across its pharmaceutical portfolio. However, the cost of materials consumed surged significantly to ₹1,208.91 lakh from ₹803.02 lakh in the previous year’s quarter, reflecting inflationary pressures in raw material costs. Employee benefits expense also increased to ₹184.63 lakh from ₹154.33 lakh, while other expenses rose to ₹285.64 lakh from ₹202.49 lakh. These cost increases outpaced revenue growth, leading to a compression in operating margins.

On a standalone basis, Kopran’s revenue from operations grew more sharply by 22.2% to ₹627.58 lakh from ₹513.35 lakh in Q1FY25. Standalone EBITDA margin remained relatively stable but showed signs of pressure, with total expenses rising to ₹568.88 lakh from ₹485.25 lakh. The company benefited from foreign exchange gains of ₹197.62 lakh on a consolidated basis and ₹258.39 lakh on a standalone basis, which partially offset the operating margin contraction.

The following table summarises Kopran’s key financial metrics for Q1FY26:

Note: EBITDA calculated as Total Income minus Total Expenses plus Depreciation/Amortisation/Finance Costs where applicable per standard definition implied by source data structure.

Profitability and Bottom Line

Despite the revenue growth, Kopran’s consolidated net profit declined to ₹670.09 lakh in Q1FY26 from ₹744.93 lakh in Q1FY25, a decrease of approximately 10%. The profit before tax stood at ₹880.29 lakh, down from ₹988.91 lakh in the prior year quarter. Tax expense for the period was ₹193.25 lakh (current tax) and ₹16.95 lakh (deferred tax), totaling ₹210.20 lakh.

In contrast, the standalone segment saw a significant improvement in net profit, which more than doubled to ₹672.30 lakh from ₹351.81 lakh in Q1FY25. This divergence highlights the impact of inter-company transactions and subsidiary performance on the consolidated bottom line. Basic earnings per share (EPS) for the consolidated entity fell to ₹1.39 from ₹1.54 in Q1FY25, while standalone basic EPS rose to ₹1.39 from ₹0.73.

What the Numbers Show

The primary challenge for Kopran in Q1FY26 was margin erosion due to disproportionate growth in material costs. While revenue grew by nearly 14%, the cost of materials consumed jumped by over 50%, indicating either a shift towards higher-cost products or significant inflation in key active pharmaceutical ingredients (APIs). The contraction in consolidated EBITDA margin from 12.22% to 11.55% underscores this pressure. However, the strong standalone profit growth suggests that the parent company’s direct operations are performing well, with efficiencies or better pricing power not fully reflected in the consolidated group results due to subsidiary dynamics. Foreign exchange gains provided a modest tailwind, contributing ₹197.62 lakh to consolidated income, but were insufficient to fully counteract the operating headwinds.

Kopran Limited reported a consolidated net profit of ₹670 lakh for the quarter ended June 30, 2026, down 10.1% from ₹745 lakh in the same period last year. Revenue from operations declined sharply by 34.2% to ₹15,399 lakh, compared to ₹23,402 lakh in Q4FY26 and ₹13,522 lakh in Q1FY26. The results highlight a contraction in operational efficiency, with EBITDA margin slipping to 10.31% from 10.57% in Q1FY26, signaling pressure on profitability amid reduced sales volumes.

The company submitted its unaudited financial results and investor presentation to BSE Limited and The National Stock Exchange of India Limited on August 07, 2026. The filing, signed by Company Secretary Sunil Sodhani, discloses that EBITDA figures exclude other income and forex losses. Kopran’s Board of Directors, led by Chairman & Managing Director Surendra Somani, oversees an integrated pharmaceutical business with verticals in Active Pharmaceutical Ingredients (APIs) and formulations, operating through its wholly owned subsidiary Kopran Research Laboratories Ltd. (KRLL).

Financial Performance

*EBITDA excluding other income and forex losses

Revenue declined significantly quarter-on-quarter from ₹23,402 lakh in Q4FY26, reflecting seasonal or operational variability. While EBITDA dropped to ₹1,588 lakh from ₹4,066 lakh in the preceding quarter, it remained slightly above the ₹1,429 lakh recorded in Q1FY26. Finance costs increased modestly to ₹328 lakh from ₹317 lakh in Q4FY26 and ₹254 lakh in Q1FY26. A forex gain of ₹198 lakh provided some offset to operating pressures, contrasting with a forex loss of ₹763 lakh in Q4FY26.

Segment-Wise Revenue Mix

The API vertical contributed ₹9,538 lakh in Q1FY27, with Anti-Diabetic APIs leading at ₹4,488 lakh. Carbapenem revenue surged to ₹2,230 lakh from ₹394 lakh in FY25-26, indicating strong demand or capacity utilization in this niche segment. Formulations revenue stood at ₹5,709 lakh, driven primarily by exports to South Africa (₹2,845.92 lakh) and Africa (₹2,084.16 lakh). Pen Plant formulations accounted for ₹3,136 lakh, while Non Pen Plant contributed ₹2,573 lakh.

What the Numbers Show

The divergence between API and formulation performance reveals shifting demand dynamics. While Carbapenem revenues grew substantially, overall API revenue mix shows concentration risk in Anti-Diabetic products, which constitute nearly 47% of API segment revenue. Meanwhile, formulation sales remain heavily dependent on African markets, which together account for over 85% of formulation revenue. This geographic and product concentration exposes Kopran to regulatory and currency risks in key emerging markets, potentially impacting future margin stability.